
Drugmaker Indivior must face a lawsuit by 42 state attorneys general accusing it of using illegal tactics to shield its opioid addiction treatment Suboxone from generic competition, a federal judge has ruled.
US District Judge Mitchell Goldberg in Philadelphia found Monday that a reasonable jury could find that Indivior’s switch from a pill to an oral film form of the drug in 2009 was intended to extend its monopoly just as generic manufacturers were poised to begin selling their own pills, a strategy known as product hopping. He denied the Virginia-based company’s motion for a judgment in its favor.
States have said that the company’s conduct forced consumers to pay inflated prices for the treatment amid an epidemic of opioid addiction.
“The cost of critical medication must not be inflated through anticompetitive tactics,” Wisconsin Attorney General Josh Kaul, who is leading the multistate coalition, said in a statement.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Fires Two Democratic FTC Members, Raising Questions Over Regulatory Independence
Mar 19, 2025 by
CPI
Spain’s BBVA Remains Optimistic About Hostile Takeover of Sabadell
Mar 18, 2025 by
CPI
BlackRock, Vanguard and State Street Seek Dismissal of Texas Antitrust Lawsuit
Mar 18, 2025 by
CPI
EU to Boost Metal Sectors with Energy Relief and Safeguards
Mar 18, 2025 by
CPI
Players’ Association Sues Tennis Governing Bodies Over Alleged Antitrust Violations
Mar 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li